1Q23 Business Results
1Q23 Business Results
Key Products
Plan & Vision
Appendix
Revenue: Increased by 21% due to the stable prescription of all products, especially with the highly profitable products such as RemsimaⓇSC and YuflymaⓇ
Operating Profit: Achieved solid operating profit through the sales of high-margin products and cost improvement in RemsimaⓇ although the SG&A has increased after
the direct sales began in the US
Net Profit: NP has improved both QoQ and YoY as a result of increased non-operating income by the weak KRW
1Q23 Business Results
(KRW bn)
'22.1Q
'22.4Q
'23.1Q
% YoY
%QoQ
Revenue
415.7
541.1
503.6
21.1%
-6.9%
Gross Profit
104.2
163.6
153.2
47.0%
-6.4%
(%)
25.1%
30.2%
30.4%
5.3%p
0.2%p
SG&A
59.2
126.3
102.2
72.6%
-19.1%
(%)
14.2%
23.3%
20.3%
6.1%p
-3.0%p
Personnel expenses
12.5
26.3
18.1
44.8%
-31.2%
Research expenses
5.0
11.6
4.6
-8.0%
-60.3%
Advertising expenses
2.9
10.5
10.2
251.7%
-2.9%
Commissions
13.4
24.6
30.1
124.6%
22.4%
Transportation expenses
7.4
13.7
13.9
87.8%
1.5%
Operating Profit
45.0
37.3
51.0
13.3%
36.7%
(%)
10.8%
6.9%
10.1%
-0.7%p
3.2%p
EBIT
61.3
(112.1)
120.1
95.9%
TP
Net Profit
43.6
(73.1)
54.1
24.1%
TP
Investor Relations 2023 3View entire presentation